BioPharma Credit PLC (OTCMKTS:BOPCF) Sees Significant Decline in Short Interest
by Scott Moore · The Cerbat GemBioPharma Credit PLC (OTCMKTS:BOPCF – Get Free Report) saw a significant decline in short interest in the month of April. As of April 15th, there was short interest totaling 1,634 shares, a decline of 99.8% from the March 31st total of 776,879 shares. Based on an average daily trading volume, of 32,200 shares, the days-to-cover ratio is presently 0.1 days.
BioPharma Credit Stock Performance
Shares of BOPCF remained flat at $0.95 during midday trading on Friday. 5,232 shares of the stock traded hands, compared to its average volume of 473,676. BioPharma Credit has a 1-year low of $0.83 and a 1-year high of $1.00. The company’s 50-day moving average is $0.91 and its 200 day moving average is $0.90.
BioPharma Credit Company Profile
BioPharma Credit (OTCMKTS: BOPCF) is a closed-end investment company that specializes in providing debt financing solutions to the global life sciences sector. The firm offers a range of credit products—including senior secured loans, convertible loans and royalty monetization structures—designed to meet the capital needs of biotechnology and pharmaceutical companies across pre-clinical, clinical and commercial stages. By focusing on secured and structured credit, BioPharma Credit seeks to deliver consistent income while managing risk through collateralized arrangements and diversified portfolios.
Since its inception in 2016, the company has built a track record of partnering with innovative drug developers and medical technology firms.